Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6163 pages
Showing 3801 - 3850
Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device
Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6...
Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy
Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have...
Eric Pujade-Lauraine, MD, PhD, on First-Line Maintenance Therapy in Ovarian Cancer
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with...
Brittany A. Davidson, MD, on a Model to Predict the Need for Opioids After Gynecologic Surgery
Brittany A. Davidson, MD, of Duke University, discusses the development and validation of the GO-POP model (Gynecologic Oncology Predictor of Postoperative opioid use), an individualized patient-centered predictive tool designed to help avoid overprescribing pain medications (ID# 10253).
Dana M. Roque, MD, on Ovarian, Fallopian Tube, and Peritoneal Cancers: Possible New Therapeutic Option for Heavily Pretreated Disease
Dana M. Roque, MD, of the University of Maryland Medical Center, discusses phase II results showing that weekly ixabepilone plus biweekly bevacizumab may improve overall response rate as well as progression-free and overall survival for women with platinum-resistant or -refractory ovarian,...
Laura Chambers, DO, on Treating Epithelial Ovarian Cancer With Cisplatin and Paclitaxel During Surgery
Laura Chambers, DO, of the Cleveland Clinic, discusses data showing that combining paclitaxel and cisplatin vs cisplatin alone with hyperthermic intraperitoneal chemotherapy at interval debulking surgery improved progression-free survival. There was no difference in postoperative complications,...
ASTRO Recommendation on COVID-19 Vaccination for Patients Receiving Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has compiled a selection of resources for radiation oncology professionals. The resources were developed by clinical teams and based on the best available information at the time they were posted. Physicians and their patients must make the...
Memorial Sloan Kettering Establishes Tow Center for Developmental Oncology
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Tow Center for Developmental Oncology (TCDO). The new institution will bring together the unique expertise of researchers and physicians from across MSK and empower them to pursue translational research...
Ravi Bellamkonda, PhD, Named Provost of Emory University
Emory University President Gregory L. Fenves, PhD, recently announced the appointment of biomedical scientist Ravi Bellamkonda, PhD, as the university’s next Provost and Executive Vice President for Academic Affairs, effective July 1, 2021. Dr. Bellamkonda returns to Emory after serving as Dean of...
Hans Clevers, MD, PhD, FAACR, Recognized With 2021 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Hans Clevers, MD, PhD, FAACR, at the virtual AACR Annual Meeting 2021, to be held April 10–15 and May 17–21. Dr. Clevers, who is...
Leading Health and Cancer Advocacy Groups Unite to Reduce Racial Disparities in Cancer Care
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF) recently presented new ideas for overcoming inequality in oncology. The recommendations—developed by a group of 17 national experts, representing...
Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide
Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...
American Cancer Society Announces New Diversity in Cancer Research Program
The American Cancer Society recently launched the Diversity in Cancer Research program, a permanent umbrella that will support the American Cancer Society’s effort to foster a more diverse scientific workforce community. This has been made possible through an endowment contribution from Elizabeth...
Prevent Cancer Foundation Awards Nine New Research Grants
The Prevent Cancer Foundation has announced funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for 2 years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone ...
SGO and FWC Issue Joint Statement on the Elimination of HPV
United in their commitment to eliminate human papillomavirus (HPV)-related cancer, the Society of Gynecologic Oncology (SGO) and the Foundation for Women’s Cancer (FWC) recently endorsed a series of vaccine recommendations. HPV vaccines are among the most effective vaccines available worldwide,...
Sara Schottenstein Foundation, Dedicated to Gastric Cancer, Announces Launch
A science-focused organization dedicated to ending gastric cancer, the Sara Schottenstein Foundation recently announced its launch and its new website, http://www.saraschottensteinfoundation.org. Founded by Jeff Schottenstein, MBA, a wealth management professional in San Francisco, the Sara...
Sachin Apte, MD, MS, MBA, Joins Huntsman Cancer Institute as Chief Clinical Officer
Huntsman Cancer Institute (HCI) and University of Utah (U of U) Health announced the appointment of Sachin Apte, MD, MS, MBA, as Chief Clinical Officer of HCI and Physician-in-Chief of the cancer hospital. “Dr. Apte will lead HCI’s clinical efforts at a time when we are poised to dramatically...
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-Designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH) have named James K. Aikins, Jr, MD, FACOG, FACS, Chief of Gynecologic Oncology at Rutgers Cancer Institute and Chief of Gynecologic Oncology Services at RWJUH. He will also serve as Program Director for the...
Patrick Delaney Named New Executive Director of NCCN Foundation
The National Comprehensive Cancer Network (NCCN) has announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation. Mr. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society. ...
Winthrop P. Rockefeller Cancer Institute Appoints New Deputy Director
Cancer researcher Alan Tackett, PhD, has been named Deputy Director of the Winthrop P. Rockefeller Cancer Institute (Cancer Institute) at the University of Arkansas for Medical Sciences (UAMS). Dr. Tackett, who is noted for his research in cancer biomarker discovery, is Professor in the UAMS...
Roswell Park, Bristol Myers Squibb Foundation Team Up to Fight Cancer in Native and Rural Communities
Roswell Park comprehensive Cancer Center and the Bristol Myers Squibb Foundation announced a $3.3 million program to address the cancer burden in rural areas and Native Nations across New York State, with an emphasis on the Western New York region. The grant from the Bristol Myers Squibb Foundation ...
Cancer Cell Therapy Pioneer Carl June, MD, Named 2021 Dan David Prize Laureate
International cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine and Director of the Center for Cellular Immunotherapies at Penn Medicine Abramson Cancer Center, has...
Development of Oral Taxane Tesetaxel to Be Discontinued
Following feedback from the U.S. Food and Drug Administration (FDA) in a pre–new drug application meeting, Odonate Therapeutics has concluded that the clinical data package for tesetaxel, an oral taxane tested in patients with metastatic breast cancer, is unlikely to support FDA approval....
Surgical Management of Melanoma With the Advent of Adjuvant Systemic Therapy
The results of a large cohort study suggest that a proportion of patients with cutaneous melanoma could potentially avoid sentinel node biopsy, according to data presented by Moncrieff et al at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care (Abstract 59)....
Rates of Seroconversion Among Patients With Cancer Infected With COVID-19
Most people with cancer who are infected with COVID-19 produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on the type of malignancy and the treatments they’ve received, according to a new study published by Thakkar et al in Nature Cancer. The...
Study Establishes Global Burden of Gallbladder and Biliary Tract Cancer
Although cancers of the gallbladder or bile ducts are rare, their rates of occurrence are increasing. A recent study published by Ouyang et al in the journal Cancer provided details on the burden of gallbladder and biliary tract cancer across 195 countries and territories from 1990 to 2017....
Shaji K. Kumar, MD, on Multiple Myeloma: NCCN Guidelines Update
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the latest data on treating patients with multiple myeloma, including standard-of-care induction before stem cell transplant; the role of quadruplet induction; long-term results with the combination of daratumumab, lenalidomide, and...
Factors Associated With Severity of COVID-19 Infection in Patients With Cancer: Data From CCC19
Updated findings from a cohort of patients with cancer infected with COVID-19 included in the COVID-19 and Cancer Consortium (CCC19) were published by Petros Grivas, MD, PhD, and colleagues in Annals of Oncology. Authors identified factors associated with a more severe viral infection among...
Outcomes of Complex Gastrointestinal Cancer Surgeries at Ranked vs Nonranked Hospitals
Patients whose procedures for gastrointestinal malignancies were performed by a surgical team at a hospital ranked as one of America’s “best” by U.S. News & World Report were nearly two and half times more likely to survive the operation than those who had the same procedure done at a nonranked ...
FDA Approves Pembrolizumab Combination for Advanced Esophageal or Gastroesophageal Junction Carcinoma
On March 22, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (tumors with epicenter 1–5 cm above the...
Gabrielle A. Zecha, PA-C, MHA, and Aaron Begue, MS, RN, NP-C, OCN: The Role of Advanced Practice Providers in Oncology Care
Gabrielle A. Zecha, PA-C, MHA, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, and Aaron Begue, MS, RN, NP-C, OCN, of Memorial Sloan Kettering Cancer Center, discuss how advanced practice providers are recruited and trained, ways to retain these valuable health-care...
Susan M. Swetter, MD, on Molecular Testing for Cutaneous Melanoma
Susan M. Swetter, MD, of Stanford Cancer Institute, discusses molecular prognostic tests for cutaneous melanoma, which may improve staging accuracy, reduce unnecessary sentinel lymph node biopsies, and inform decisions on surveillance imaging and/or adjuvant therapy.
Supriya Chopra, MD, on Cervical Cancer: Reducing Late Effects of Bowel Toxicity
Supriya Chopra, MD, of Tata Memorial Centre, discusses a final analysis of the phase III PARCER trial, which showed that image-guided intensity-modulated radiotherapy is superior to conventional radiotherapy in reducing bowel toxicity in women with cervical cancer. Acute diarrhea was also reduced,...
Lauren Thomaier, MD, on Predicting Chemotherapy-Induced Peripheral Neuropathy in Gynecologic Cancer Survivors
Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important...
Emily Hinchcliff, MD, MPH, on Treating Non–Clear Cell Ovarian Cancer With Durvalumab and Tremelimumab
Emily Hinchcliff, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses phase II results of durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) administered in combination vs sequentially for the treatment of recurrent platinum-resistant non–clear cell ovarian cancer (ID...
Sandro Pignata, MD, PhD, on BRCA-Mutated Ovarian Cancer: Maintenance Olaparib Outcomes
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, discusses results from the ORZORA trial, which showed the efficacy of olaparib in patients with platinum-sensitive relapsed ovarian cancer is similar, whether they have a germline or somatic BRCA mutation. This information could prove...
Alice P. Barr, MD, on Advanced Ovarian Cancer: Minimally Invasive vs Open Surgery After Chemotherapy
Alice P. Barr, MD, of the Carolinas Medical Center and Levine Cancer Institute, discusses results from a retrospective study, which showed that progression-free and overall survival appeared to be no different with open surgery and minimally invasive surgery for interval debulking after neoadjuvant ...
KRAS Mutation Status May Predict Outcomes After Hepatic Arterial Infusion Pump Therapy for Unresectable Colorectal Liver Metastases
KRAS mutational status in patients with unresectable liver metastases from colorectal cancer predicts a worse response to hepatic arterial infusion (HAI) pump chemotherapy, according to research presented by Kolbeinsson et al at the Society of Surgical Oncology 2021 International Conference on...
Older Patients With Multiple Myeloma May Be Able to Avoid Long-Term Steroid Use
The combination of lenalidomide plus the steroid dexamethasone (together called Rd) is considered standard treatment for elderly patients with multiple myeloma. However, prolonged steroid use can be harmful for some older adults. A new study published by Larocca et al in the journal Blood found...
Charles N. Landen, MD, on Newly Diagnosed Ovarian Cancer: BRCA Mutations, PD-L1 Expression, and Combination Chemoimmunotherapy
Charles N. Landen, MD, of the University of Virginia, discusses results from the first clinical trial in ovarian cancer to demonstrate that neither a BRCA1/2 mutation nor a homologous recombination deficiency improves sensitivity to a therapeutic PD-L1 blockade in patients receiving atezolizumab vs ...
Hyun C. Chung, MD, on Pembrolizumab for Advanced Cervical Cancer: Update From KEYNOTE-158
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose...
Hormonal IUD May Be a Potential Nonsurgical Treatment for Early Endometrial Cancer or Precancer
An intrauterine device, or IUD, that releases the hormone levonorgestrel appears to be an effective treatment for endometrial precancer and early-stage endometrial cancer, according to new study results presented by Andreas Obermair, MD, at the Society of Gynecologic Oncology (SGO) 2021 Virtual...
Shannon N. Westin, MD, on Treating Endometrial Cancer With Enzalutamide, Paclitaxel, and Carboplatin
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin yielded promising clinical outcomes in chemotherapy-naive advanced or recurrent endometrioid cancer ...
Ursula A. Matulonis, MD, on Ovarian Cancer: Niraparib as Maintenance Therapy
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ENGOT-OV16/NOVA study on the long-term safety and efficacy of niraparib as maintenance therapy in patients with platinum-sensitive ovarian cancer with either a BRCA mutation or a tumor with high-grade...
Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer
Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all...
Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research
Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).
Edward L. Trimble, MD, MPH, on Cervical Cancer: A Global WHO Initiative
Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, treatment, and training for multidisciplinary teams in gynecologic oncology care. This marks the first...
William H. Bradley, MD, on Ovarian Cancer: 5-Year Follow-up on Maintenance Olaparib
William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib...
Recent Chemotherapy or Immunotherapy for Gynecologic Cancer Does Not Raise Risk of Death Due to COVID-19
Although some studies show that patients with cancer have a greater risk of health complications from COVID-19, a new study has found that recent chemotherapy or immunotherapy for gynecologic cancer does not raise the risk of hospitalization or death due to COVID-19. The study results were...
Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy
Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated,...
